Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

THOUSAND OAKS, Calif., Dec. 21, 2020 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticoster... Biopharmaceuticals Amgen, AstraZeneca, tezepelumab, asthma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news